Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced that Graham Brearley, PhD, has been appointed as General Manager of the company’s Madison, Wisconsin facility. He will report to Brian Riley, Vice President of Operations, Biologics & Specialty Drug Delivery.
 

In his most recent position, Dr. Brearley served as Senior Director, Technical Operations with Shire, where he was responsible for leading strategy, organization, execution and business processes. With a proven track record in providing technical expertise on operational aspects of the bioscience business, including process development and life cycle management, he has over 25 years’ technical, operations and business experience in the biopharmaceutical industry.
 

Prior to that, Dr. Brearley held leadership positions at organizations including Sigma-Aldrich and Baxter. He has a bachelor’s degree in applied biology from Thames Polytechnic, U.K. and a doctorate in biochemistry from the Council of National Academic Awards.

 

Opened in April 2013 and recently expanded, Catalent Biologics’ Madison facility provides development, manufacturing and analytical services for new biological entities and biosimilars, and is the home of the company’s proprietary GPEx cell line technology, used to create high-yielding mammalian cell lines. The Madison facility was designed for flexible cGMP production, from 10 to 4,000-liter scale, and non-GMP production up to 250-litre scale, and features extensive use of single-use technologies and unidirectional flow to maximize efficiency. Manufacturing is supported by integrated analytical, process and formulation development capabilities and separate microbiology and quality control functions.